Medical Xpress·· 4 小时前AI 评分74
sacituzumab tirumotecan使既往治疗的晚期或复发性子宫内膜癌进展风险降低41%、死亡风险降低32%
Next-generation drug reduces endometrial cancer progression and death in trial
AI 导读
III期随机试验TroFuse-005/ENGOT-en23/GOG-3095显示，sacituzumab tirumotecan（sac-TMT）较标准化疗使晚期或复发性子宫内膜癌患者的疾病进展风险降低41%、死亡风险降低32%。
来源：Medical Xpress · medicalxpress.com